38 results about "Ginsenoside F1" patented technology

The invention discloses applications of glycosyltransferase and related materials thereof in the construction of engineering bacteria for producing ginsenoside Rb1 and Rg1. A glycosyltransferase genePn3-32 which can catalyze ginsenoside Rd to generate ginsenoside Rb1 can be successfully identified through a synthetic biological method; and the gene can simultaneously catalyze ginsenoside F1 to generate ginsenoside Rg1 and construct recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1. Through experiments, the constructed recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1 can simultaneously generate the ginsenoside Rb1 and the ginsenoside Rg1. Pn1-31, Pn-3-29, Pn3-31 and Pn3-32 glycosyltransferase genes in medicinal plant radix notoginseng are firstly utilized to continuously catalyze protopanaxadiol and protopanaxatriol to synthetize the ginsenoside Rb1, the ginsenoside Rg1 and corresponding intermediates, so that novel cases can be provided formicrobial strains to produce natural products.

A process for preparing ginsenoside monomer from ginseng leaf includes such steps as preparing general ginsenoside from ginseng leaf, chromatography with alumina column to obtain several groups of ginsenosides, and chromatography by column to obtain different ginsenoside monomers.

Disclosed herein is nanoemulsion prepared by emulsifying main metabolites of ginseng saponin obtained by conversion of glucose, i.e. compound K (20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol), ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) and compound Y (20-O-[α-L-arabinopyranosyl(1→6)-β-D-glucopyranosyl]-20(S)-protopanaxadiol); and admixture-thereof, in fine emulsion or liposome with dermotropic emulsifier by nano-emulsification; and having enhanced skin penetration, so to be effective in promoting proliferation of fibroblast and biosynthesis of collagen.

Disclosed is the use of Ginsenoside F1 in preparing medicament for the treatment of Parkinson's disease.

Disclosed is the use of Ginsenoside F1 in preparing medicament for the treatment of vascular dementia and Alzheimer's disease.

The invention provides a method for determining content of six ginsenoside ingredients of folium ginseng. Ginsenoside is the main active ingredient of the folium ginseng and an important criterion for measuring the quality of the folium ginseng, but the content is greatly different from that of ginseng. According to the method, ultra-high performance liquid chromatography is used for determining the six ginsenoside ingredients including ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rb2, 20(S)-ginsenoside F1 and ginsenoside Rd in the folium ginseng simultaneously, the method is high in sensitivity and accurate, and can be used for quality control of the folium ginseng.

Disclosed is the use of Ginsenoside F1 in preparing medicament for the treatment of cataract.

Disclosed herein is a whitening cosmetic composition containing plant-derived ginsenoside Fl (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) as an active ingredient. More specifically, the ginsenoside Fl is obtained from particularly a ginseng extract using an acid, a base, an enzyme or microorganism, and a whitening cosmetic composition containing the ginsenoside Fl has an excellent effect of inhibiting melanin biosynthesis, and thus provides an excellent skin whitening effect.

Disclosed is the use of Ginsenoside F1 in preparing medicament for the treatment of regenerative anemia.

Disclosed is the use of Ginsenoside F1 in preparing medicament for the treatment of ischemic heart disease and ischemic cerebrovascular diseases.

The invention discloses a preparation method of ginsenoside F1. The method comprises the steps that genes PnDDS, P12H, D6H and UGTPn20 are simultaneously transferred into a tobacco to obtain a transgenic tobacco capable of synthesizing the ginsenoside F1, wherein the nucleotide sequence of the gene PnDDS is as shown in SEQ ID NO: 1, the nucleotide sequence of the gene P12H is as shown in SEQ ID NO: 2, the nucleotide sequence of the gene D6H is as shown in SEQ ID NO: 3, and the nucleotide sequence of the gene UGTPn20 is as shown in SEQ ID NO: 4. Experimental results show that an obtained transgenic tobacco plant can synthesize the ginsenoside F1, so that the ginsenoside F1 can be obtained more efficiently and conveniently, the method is simple, easy to operate and suitable for large-scale production and market popularization and application, and a new way is provided for obtaining the ginsenoside F1.

The invention discloses a lactobacillus plantarum proliferation agent and applications thereof. The proliferation agent is the fermentation supernatant of B.subtilis sp CGMCC 18057; 6'-acetyl ginsenoside F1 is also included; and the fermentation supernatant is obtained in a culture medium containing soybean components through fermentation. The proliferation agent is simple in preparation method and low in cost; the used strain of the proliferation agent is probiotics, so that other health probiotic effects can be enhanced; and the prepared proliferation agent has significant promotion effectson the growth of lactobacillus plantarum in milk, so that the application space and application potential of the lactobacillus plantarum in actual product development can be greatly enhanced.

The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

The invention discloses a method used for preparing 6'-acetyl ginsenoside F1. The method comprises following steps: 1, ginseng buds are collected, smashed, and are subjected to heat backflow extraction with 95% ethanol, and concentration into paste is carried out so as to obtain a total extracted product; 2, the total extracted product is prepared into a solution with a concentration of 0.2g crudedrug/ml with 25% ethanol, filtering is carried out, and column chromatography is carried out, wherein sample injection amount is 0.8BV, LX-68 macroporous adsorption resin column column bed diameter height ratio is controlled to be 1:9, 3BV of 40% ethanol is adopted for impurity removing, 9BV of 75% ethanol is adopted for elution, 8 to 9 BV of 75% ethanol eluate is collected, pressure reduced concentration is carried out until no ethanol is detected, and then freeze-drying is carried out so as to obtain a crude freeze-dried powder; and 3, high speed counter current separation is carried out, wherein n-butanol/ethyl acetate/methanol/water/chloroform solvent system ratio is controlled to be 1:18:1:18:0.5, the elution fractions corresponding to 6'-acetyl ginsenoside F1 are collected based ona chromatogram, and concentration is carried out so as to obtain 6'-acetyl ginsenoside F1.

The invention discloses a method for preparing 3-acetyl ginsenoside F1. The method comprises the following steps: 1, taking ginseng flower buds, crushing the ginseng flower buds, performing hot refluxing extraction by using 95% ethanol, and concentrating the obtained solution to form a paste which is total extract; 2, dissolving the total extract in 25% ethanol to adjust the concentration to 0.2 gcrude drug/mL, filtering the obtained solution, adding 0.8 BV of the filtered solution into an LX-68 macro-porous adsorption resin column with a column bed having a diameter-to-length ratio of 1:9, removing impurities by using 3 BV of 40% ethanol, then performing elution with 9 BV of 75% ethanol, collecting 8-9 BV of 75% ethanol eluate, performing reduced pressure concentration until no alcohol smell appears, and lyophilizing the obtained concentrate to obtain a crude lyophilized powder; and 3, performing high-speed countercurrent separation with the solvent system being n-butanol/ethyl acetate/methanol/water/chloroform having a volume ratio of 1:18:1:18:0.5, collecting an elution fraction corresponding to the 3-acetyl ginsenoside F1 according to obtained chromatogram, and concentrating the elution fraction until the elution fraction is dry in order to obtain the 3-acetyl ginsenoside F1.

The invention discloses novel application of a ginsenoside F1 medicament and in particular relates to application of the ginsenoside F1 in preparation of medicaments for preventing and treating atherosclerosis and coronary atherosclerotic heart disease.

The invention discloses application of rare ginsenosides, and particularly relates to application of rare ginsenoside F1, rare ginsenoside F2 and/or rare ginsenoside F3 in intelligence development, intelligence deterioration prevention and neurodegenerative disease prevention and treatment. The rare ginsenosides F1, F2 and F3 are found to have the activity of inhibiting cell beta secretase, so that the effect of reducing the generation of A beta amyloid protein is achieved, and hypophrenia and neurodegenerative diseases caused by the A beta amyloid protein are avoided.